$11.19
0.72% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US18507C1036
Symbol
CLPT
Sector

ClearPoint Neuro Stock price

$11.19
-1.56 12.24% 1M
+4.47 66.52% 6M
+4.40 64.80% YTD
+6.06 118.13% 1Y
-7.59 40.42% 3Y
+7.19 179.75% 5Y
+7.19 179.75% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.08 0.72%
ISIN
US18507C1036
Symbol
CLPT
Sector

Key metrics

Market capitalization $306.59m
Enterprise Value $287.54m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 10.24
P/S ratio (TTM) P/S ratio 10.92
P/B ratio (TTM) P/B ratio 9.54
Revenue growth (TTM) Revenue growth 29.33%
Revenue (TTM) Revenue $28.07m
EBIT (operating result TTM) EBIT $-18.57m
Free Cash Flow (TTM) Free Cash Flow $-9.73m
Cash position $32.85m
EPS (TTM) EPS $-0.71
P/E forward negative
P/S forward 9.78
EV/Sales forward 9.18
Short interest 2.64%
Show more

Is ClearPoint Neuro a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

ClearPoint Neuro Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a ClearPoint Neuro forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a ClearPoint Neuro forecast:

Buy
100%

Financial data from ClearPoint Neuro

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
28 28
29% 29%
100%
- Direct Costs 11 11
35% 35%
40%
17 17
26% 26%
60%
- Selling and Administrative Expenses 23 23
9% 9%
81%
- Research and Development Expense 11 11
15% 15%
39%
-17 -17
17% 17%
-60%
- Depreciation and Amortization 1.78 1.78
91% 91%
6%
EBIT (Operating Income) EBIT -19 -19
12% 12%
-66%
Net Profit -18 -18
14% 14%
-64%

In millions USD.

Don't miss a Thing! We will send you all news about ClearPoint Neuro directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ClearPoint Neuro Stock News

Neutral
GlobeNewsWire
about one month ago
ClearPoint Neuro clears all debt from balance sheet after early repayment of principal & interest on $10 million convertible note held by PTC Therapeutics
Positive
Seeking Alpha
about one month ago
ClearPoint's business is gaining momentum, with recent growth investments starting to pay off. Growth in system placements is an early indication of the potential boost that the OR system and laser therapy will provide. ClearPoint's biologics business also continues to progress. This was highlighted recently by uniQure's solid clinical trial data.
Positive
Seeking Alpha
about 2 months ago
ClearPoint Neuro is an industry leader in providing tools for minimally invasive brain surgeries, neurosurgical laser therapy, and drug delivery to the brain. The company has established a deep moat by working with partners early in clinical work, making its products part of FDA submissions. Continuous growth is expected through partner programs, consulting fees, and possible royalties and mile...
More ClearPoint Neuro News

Company Profile

Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Solana Beach, CA.

Head office United States
CEO Joseph Burnett
Employees 107
Founded 1998
Website www.clearpointneuro.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today